TRANSPOD
29.3.2022 13:02:07 CEST | Business Wire | Press release
TransPod , the startup building the TransPod Line – a new ultra-high-speed transportation system, to disrupt and redefine commercial transportation – today announced the next phase of the multibillion-dollar infrastructure project in Alberta, Canada. Broughton Capital Group (“BCG”), in cooperation with China-East Resources Import & Export Co. (“CERIECO”), have agreed in principle to provide a combined US$550M finance and Master EPC arrangement respectively to accelerate development of a TransPod Line between Edmonton and Calgary and drive economic growth in the region. An already-released feasibility study on the TransPod Line confirmed that this ultra-high-speed transportation project will create up to 140,000 jobs and add $19.2B to the region’s GDP throughout construction, and the Master EPC arrangement is expected to involve significant contribution from Canadian contractors.
“As the first and only company to confirm such finance for a multibillion-dollar tube-transportation infrastructure project, TransPod is proud of its commitment to driving growth in Alberta through true innovation and partnership,” said Sebastien Gendron, co-founder and CEO, TransPod. “The construction and operation of a TransPod Line will help Albertans move around easily, create new jobs, and facilitate investment into the region. With the confidence of our investors and the Government of Alberta, we will deliver on a joint vision of a progressive, sustainable, and growing economy.”
Key highlights from the Alberta TransPod feasibility study include the following:
- Substantial economic growth: The Alberta TransPod Line will add $19.2 billion (or 6.25 per cent) to the province’s GDP by the year 2030.
- Significant employment growth: The Alberta TransPod infrastructure project will create 15,600 jobs per year, totaling 140,000 jobs over nine years.
- Improved affordability for travellers: Riding TransPod will take 45 minutes from Calgary to Edmonton, at an estimated ticket cost of $90 CAD, compared to more than three hours spent driving or a plane ticket costing about $162.
- Reduction in carbon footprint: Over the course of a year, the expected ridership between Calgary and Edmonton will reduce CO2 emissions by 636,000 tonnes per year, or the equivalent of planting a forest four times bigger than Calgary.
“One of BCG’s strategic goals is to invest in innovative projects and our alignment with CERIECO for the TransPod project suits that objective strongly and bodes well for future projects. We are looking forward to moving this forward,” said Broughton Capital Group.
The next phases of the Alberta TransPod project are as follows:
- Short-term: Research and development; construction permit; environmental assessment; land acquisition (present-2024)
- Medium-term: Test track construction, high-speed tests, and certification (2023-2027)
- Long-term: Construction of a full inter-city line between Edmonton and Calgary (to begin in 2027)
“Our partnership with BCG and TransPod offers strong alignment of strategic goals, a complimentary approach to infrastructure development that we believe will add significant value across innovative projects in Canada,” said CERIECO.
To support regional job development and provide employee training for the TransPod Line in Alberta, TransPod has partnered with Building Trades of Alberta to leverage its regional expertise and partner network.
“TransPod is an exciting, game-changing leader for the future of green infrastructure and transportation in Canada and beyond,” said Terry Parker, Executive Director, Building Trades of Alberta. “Not only will it help Canada tackle its carbon goals, the Alberta TransPod project will create thousands of well-paying, community-supporting jobs for Alberta’s skilled trades workers, including those from Indigenous communities, women, new Canadians, and apprentices. The Building Trades of Alberta — and its more than 60,000 members — is ready and excited to be part of this project.”
Colliers Capital Markets , a subsidiary of Colliers International, acted as financial advisor to TransPod.
About TransPod Inc.
TransPod’s goal is to disrupt and redefine commercial transportation between major cities in developed and emerging markets. The startup was founded in 2015 to build the world’s leading tube-transportation system (the TransPod Line ) to connect people, cities, and businesses with high-speed transportation that is affordable and environmentally sustainable. TransPod Inc. is headquartered in Toronto, Canada.
Visit www.transpod.com to learn more.
About Broughton Capital Group
Broughton Capital Group (BCG) is a UK based project finance funder, in which our specialism as arranger and provider of debt finance as senior lender, is with a focus on a variety of project sectors worldwide in both the public and private sectors. We are highly experienced with a first-class team internally and externally. As an alternative finance provider, we aim to provide finance solutions not always available in the conventional project finance market and as such we strive to be creative, flexible and competitive in the finance terms we can offer as lender.
Visit www.broughton-capital.com to learn more.
About CERIECO
Established in 1993, CERIECO is a Chinese state-owned enterprise with projects in over 30 countries. CERIECO is a general EPC contractor with specializations in infrastructure and real- estate construction, and export credit finance. CERIECO operates in Canada under CERIECO Canada Corp.
Visit www.cerieco.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005062/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom